Trilogy International Partners Inc T.TRL.WT.A

RE:RE:RE:RE:RE:RE:Insight

[MelnykWasRight]

Of course you stand by your nonfactual statements,

Go back through your previous posts (the ones with your non-sensical math calculations).  Look at your US sales force figure and apply that to your logic (I realize your numbers are not logical or factual for that matter).  This money might get them past June (if Natesto USA sets all time sales figures for a new drug).

Go look at current prescription numbers for Natesto in the USA.  Multiply that times roughly $211 USD (average cost of Natesto prescription in USA, that's the co-pay price, cash price is $414 USD).  Suffice it to say that people without insurance in the USA won't use this product.  Now let's calculate how many USA prescriptions are needed just for Acerus to simply break even here in Canada.  Remember to factor in that the dollar values above are gross and Acerus only gets a percentage.  There is no way that money they just obtained for diluting our shares will last to anywhere near 2021, sorry.  Unless management has shared their specific business plan with you, you have nothing to base any of your statements on.

We still don't know what the impact of CoVid19 will be.  Many ingredients for prescription drugs come out of China and India and shortages have already begun to surface.  If the Germany manufacturing of Natesto is affected by this, say good-bye.

What's in the Acerus plan for that,  SNOWFLAKE?